The strong response rates and durability in difficult-to-treat cancers validate IMA203CD8's potential across multiple indications. Traders should watch for RP2D determination later in 2026 and additional data in H2 2026, which could serve as further catalysts. The small sample sizes warrant caution, but the data positions Immatics favorably in the PRAME-targeted space.
Price Chart
Executive Summary
Immatics reported updated Phase 1 data for IMA203CD8 PRAME cell therapy at ASCO 2026, showing 63% ORR (50% cORR) in heavily pretreated gynecologic cancers including 4 complete responses, and 67% ORR (64% cORR) in synovial sarcoma with durable responses up to ~3 years. Safety profile was manageable. Data supports continued development in multiple solid tumors, with RP2D expected in 2026.
Key Facts
- IMA203CD8 achieved 63% ORR and 50% confirmed ORR in gynecologic cancers (19 evaluable patients at clinically relevant doses), including 2 confirmed and 2 unconfirmed complete responses.
- In synovial sarcoma, 67% ORR and 64% confirmed ORR (12 patients), with 1 complete response and longest response ongoing at ~3 years.
- Safety profile manageable with expected low-grade CRS; no IMA203CD8-related Grade 5 events.
- RP2D determination remains expected in 2026; updated durability data planned for H2 2026.
- PRAME is expressed in >50 cancers; clinical activity observed across distinct tumor types and varying PRAME expression levels.
Financial Impact
Positive clinical catalyst with potential to accelerate development and enhance partnership value, though Phase 1 data is preliminary.
Risk Factors
- Phase 1 data from small patient cohorts may not predict results in larger trials.
- Competition from other PRAME-targeted therapies and alternative modalities.
- Regulatory and manufacturing risks as development progresses to later stages.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303876 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.45 $8.50 | ▼ −10.05% | ▼ −10.31% | $7.59 (−19.68%) |
Aug 26, 2026 5w ago | 6-K | $9.36 $8.33 | ▲ +11.00% | ▲ +10.50% | $7.59 (+18.91%) |
Aug 18, 2026 6w ago | 6-K | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.59 (−16.50%) |
Aug 18, 2026 6w ago | Press Release | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.59 (−16.50%) |
Jun 2, 2026 17w ago | 6-K | $10.04 $9.85 | ▼ −1.89% | ▼ −0.33% | $7.59 (−24.40%) |
Jun 1, 2026 17w ago | 6-K | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
Jun 1, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 31, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 30, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 12, 2026 20w ago | 6-K | $11.39 $8.87 | ▲ +22.12% | ▲ +20.40% | $7.59 (+33.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access